Monday, July 4, 2022

561.316.3330

Aristea Therapeutics Announces Key Leadership Appointments

Ciara Kennedy, Founder, President and Chief Executive Officer of Sorriso Pharmaceuticals, is Chair of the Board of Directors of Aristea Therapeutics and Fabio Magrini, clinical research leader in chronic inflammatory and autoimmune diseases, is Executive Medical Director of Aristea Therapeutics

Latest Posts

Worldwide Biopharmaceuticals Contract Manufacturing Industry is Expected to Reach $67.9 Billion by 2027

The Global Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 27.99 billion in 2021 and expected to reach USD 32.37 billion in 2022, and is projected to grow at a CAGR 15.92% to reach USD 67.93 billion by 2027.

Global Chromatography Accessories and Consumables Market Analysis Report 2022: Market to Reach $14.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Chromatography Accessories and Consumables market estimated at US$10.1 Billion in the year 2020, is projected to reach a revised size of US$14.7 Billion by 2027, growing at a CAGR of 5.5% over the analysis period 2020-2027.

Lupus Nephritis Market Insight, Epidemiology and Market Forecast 2032

In the coming years, the Lupus Nephritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

ROME Therapeutics notes the study reveals first-ever structure of a non-viral endogenous reverse transcriptase. Human endogenous retrovirus-K (HERV-K) RT shows striking similarity to HIV RT. The findings enable structure-based drug discovery for eRTs

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of Ciara Kennedy as Aristea Therapeutics’ Chair of the Board of Directors and Fabio Magrini as Executive Medical Director.

James M. Mackay, Ph.D., President and CEO of Aristea, commented, “Ciara and Fabio are invaluable members of our Board and management teams, respectively. Both scientists, collectively bring decades of experience in our industry to the company. Their contributions moving forward will be crucial, as we move our lead drug, RIST4721, through the clinic for palmoplantar pustulosis and additional inflammatory and autoimmune diseases.”

“I’m delighted to expand my role with Aristea at such a dynamic time for the company,” said Dr. Kennedy. “Following last year’s successful Series B financing and our auspicious collaboration agreement with Arena Pharmaceuticals, Aristea is well-positioned to make significant strides in developing RIST4721 for a wide range of neutrophil-mediated inflammatory indications.”

“It is truly an honor to join Aristea and be part of such an exceptional team,” said Dr. Magrini. “I’m humbled and excited by the opportunity to contribute to the success of such a dynamic and innovative organization dedicated to easing the suffering of patients in a growing range of inflammatory and autoimmune diseases with no or few treatment options.”

Dr. Kennedy, currently a member of Aristea’s Board of Directors, is an experienced executive with a proven track record of delivering significant results and advancing therapeutic and diagnostic programs across multiple therapeutic areas and stages of development in the biotech industry. She is the founder, President and Chief Executive Officer of Sorriso Pharmaceuticals. Previously, Dr. Kennedy was President and Chief Executive Officer of Amplyx Pharmaceuticals until the company’s acquisition by Pfizer, where she successfully raised over $150M to develop novel treatments for immunocompromised patients. Dr. Kennedy served as Chief Operating Officer at Lumena Pharmaceuticals until the company’s acquisition by Shire Pharmaceuticals and as Vice President, Head of Cholestatic Liver Disease at Shire post-acquisition. She has also served in several positions at Cypress Bioscience Inc., where she played a key role in the company’s FDA approval and launch of Savella® for Fibromyalgia; as well as at the Program and Alliance department of Biogen Idec. A Ph.D. scientist by training, Dr. Kennedy received her doctorate at the Queen’s University of Belfast, Northern Ireland.

Dr. Magrini brings 20 years of industry experience designing and implementing clinical programs in chronic inflammatory and autoimmune diseases across several therapeutic areas, including neurology, rheumatology, nephrology, and dermatology, to his role. He previously served as Principal Medical Director, Neuroimmunology and Medical Director, Neuroscience at Genentech Inc., and as Senior Medical Director at MedImmune, LLC. He gained earlier experience as a researcher at Roche and Pfizer Inc. A Rome native, Dr. Magrini qualified in Medicine and Surgery at University of L’Aquila, Italy, and later moved to England where, before joining the pharmaceutical industry, he worked at Cambridge University Department of Pathology, Human Molecular Genetics, and at Addenbrooke’s Hospital as a Clinical Fellow in Dermatology.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine